Understanding Your Prognosis and Risk Scores

In many cancers, doctors use “stages” (like Stage I or Stage IV) to describe how far a disease has spread. However, because CMML is a blood cancer that is present throughout your bone marrow and blood from the start, “staging” doesn’t apply. Instead, specialists use risk scoring models to predict how your specific version of CMML might behave over time ^[1].

These models are like sophisticated calculators. They combine your blood counts, your bone marrow findings, and your genetic mutations to estimate two key things: your likely survival and your risk of the disease transforming into Acute Myeloid Leukemia (AML) ^[2].

The Primary CMML Risk Models

There are several models validated specifically for CMML, and your doctor may use one or more of them to get a complete picture of your health.

• CPSS-Mol (CMML-Specific Prognostic Scoring System - Molecular): This widely used model factors in genetic mutations (ASXL1, NRAS, SETBP1, and RUNX1), transfusion needs, white blood cell counts, and bone marrow blast percentages ^[2][3].
• Mayo Molecular Model (MMM): This is a streamlined tool that looks for five “adverse” factors: a specific “truncating” mutation in the ASXL1 gene, a monocyte count over 10 x 10⁹/L, hemoglobin less than 10 g/dL, platelets less than 100 x 10⁹/L, and the presence of immature myeloid cells in the blood ^[4][5].
• iCPSS / IPSS-M: iCPSS is a newer integrated model that uses a larger panel of mutations to provide a precise risk calculation for CMML. You may also hear about IPSS-M, but this was primarily developed for Myelodysplastic Syndromes (MDS) rather than CMML, so its use in CMML is still being evaluated by specialists ^[6][3].

Factors That Impact Your Score

When your care team calculates your risk score, they are looking at several clinical and biological markers:

• Genetic Mutations: Certain mutations act as “red flags.” ASXL1 (specifically “truncating” mutations), RUNX1, SETBP1, and mutations in the RAS pathway (like NRAS or KRAS) are often associated with more aggressive disease ^[2][7].
• Blood Counts: Severe anemia (hemoglobin <10 g/dL), low platelets (<100 x 10⁹/L), and high white blood cell counts (proliferative phenotype) generally increase the risk score ^[4][2].
• Blast Percentage: The more immature “blast” cells found in your bone marrow or blood, the higher the risk score ^[2].
• Transfusion Dependence: If you regularly require red blood cell transfusions to manage anemia, this is often factored in as a sign of more advanced disease ^[2].

The Limitations of Risk Models

It is vital to remember that these models are based on population averages, not individual certainties. They are tools to help doctors make treatment decisions, such as when to recommend a stem cell transplant, but they cannot predict your specific future ^[1].

Furthermore, these models often focus only on the cancer itself. They may not account for:

• Your Age and Performance Status: A “high-risk” score in a very fit 40-year-old may lead to a different treatment plan than in an 85-year-old with limited mobility ^[8].
• Comorbidities: Other health issues, like heart or kidney disease, are often measured separately using tools like the Charlson Comorbidity Index or transplant-specific frailty assessments. These health factors can be just as important as the CMML score in determining your overall outlook and treatment fitness ^[9][10].
• Clonal Evolution: Your CMML can change over time. A risk score calculated at diagnosis may need to be updated if your blood counts or mutations shift later on ^[6].

Risk of AML Transformation and Survival

One of the primary concerns with CMML is the risk that it will change into Acute Myeloid Leukemia (AML). Overall, about 15% to 30% of patients will experience this transformation within 3 to 5 years of diagnosis ^[2].

Different models provide varying estimates for survival and transformation. For example, in the Mayo Molecular Model (MMM), median overall survival ranged from 97 months (low risk) to 16 months (high risk) ^[4]. In the CPSS-Mol development cohort, median overall survival spanned from more than 144 months for low risk to 18 months for high risk, with 4-year AML transformation risks varying significantly based on specific mutations like RAS ^[2][3].

Median survival means that in a large group of people with that score, half lived longer than that time and half lived less. Some people live much longer or shorter than the median. These figures are not a personal prediction, and they will be influenced by your symptoms, your body’s response to treatment, and your overall health.